Lakefront Biotherapeutics NV

Immunology (biotech)

LKFT · Nasdaq · Belgium

Share price · LKFT

$34.07+6.08 (+21.72%) 3M

close as of 2026-11-18 · 24h delayed · vol 148K (0.6x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when LKFT's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 15 Sep 2026+4.5%
  2. 12 Aug 2026-2.8%
  3. 11 Aug 2026+6.8%
  4. 23 Jul 2026-2.3%

    Nothing announced by LKFT that day or the session before.

  5. 11 May 2026-4.0%

    Nothing announced by LKFT that day or the session before.

  6. 8 May 2026+3.1%

    Nothing announced by LKFT that day or the session before.

  7. 24 Mar 2026-6.6%

Share of unusual movement by asset

For each asset, the share of LKFT's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
Other company news (earnings, financing, releases naming no asset)—46%
Sessions with no dated event—54%

No dated announcements about its assets since 2 Jul 2024.

Assets

(1 total)
1Total Assets
0Approved
1Phase 3 / Filed
0Phase 1–2 / Early
1Diseases
Showing 1 of 1 assets
Target & Modality
Phase 3
BCMA x CD3Multispecific antibody
Multiple Myeloma

Discontinued programmes (4)

Development of these assets stopped. Each page states the sourced discontinuation and keeps the trials as evidence history.

Upcoming events

(4 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (1)
December 2026 (1)
Gamgertamig (CM336)Phase 1/2Multiple Myeloma
Est. primary completion 2026-12 · NCT05299424 · CT.gov ↗
What to watch
2027 (2)
September 2027 (1)
Gamgertamig (CM336)Phase 3Multiple Myeloma (MM)
Est. primary completion 2027-09 · NCT07181239 · CT.gov ↗
What to watch
November 2027 (1)
Gamgertamig (CM336)Phase 1/2Autoimmune Cytopenia, Immune Thrombocytopenia (ITP), Autoimmune Hemolytic Anemia, Evans Syndrome
Est. primary completion 2027-11-18 · NCT07175493 · CT.gov ↗
What to watch
2030 (1)
May 2030 (1)
Gamgertamig (CM336)Phase 3Multiple Myeloma (MM)
Est. primary completion 2030-05 · NCT07910903 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

18 December 2025Topline resultCadefrecitinibGALACELA (NCT05856448) in SLE did not meet its primary endpoint (SRI-4 at week 32)

Financial reports

Quarterly & interim (11)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q1—$35M$3.4B—report ↗
View 10 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-H1$153M$304M$3.6B$283Mreport ↗
2025-Q1$79M$192M$3.6B$161Mreport ↗
2024-H1$152M$157M$3.7B—report ↗
2024-Q1$68M$78M$3.8B—report ↗
2023-H1$355M$229M$4.2B—report ↗
2023-Q1$192M$111M$4.4B—report ↗
2022-H1$300M$273M$4.6B$35Mreport ↗
2022-Q1$153M$112M$5.2B$15Mreport ↗
2021-H1$334M$324M$6.0B$66Mreport ↗
2021-Q1$150M$157M$6.0B—report ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$1.3B$521M$3.5B$214Mreport ↗

For fiscal year 2025, Lakefront Biotherapeutics NV reported revenue of $1,260.73M, up 322.7% YoY, and R&D spend of $520.75M, up 43.4% YoY. Cash and equivalents were $3,524.63M, net income was $363.73M, and quarterly net burn was $214.35M.

View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY$298M$363M$3.5B—report ↗
2023-FY$848M$261M$4.1B—report ↗
2022-FY$289M$284M$4.4B—report ↗
2021-FY$574M$582M$5.3B$668Mreport ↗

Insider transactions

This company files with the SEC but has no Section 16 insider reports. This is typical for foreign private issuers, which are exempt from Form 4 reporting.

Institutional holders

From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 89 reporting institutions held 31.3M shares ($935.1M, 47.4% of shares outstanding).

#InstitutionSharesValue
1GILEAD SCIENCES, INC.16,707,477$501.2M
2TANG CAPITAL MANAGEMENT LLC3,785,991$113.6M
3Madison Avenue Partners, LP2,465,179$74.0M
4EcoR1 Capital, LLC1,667,119$50.0M
5Prosight Management, LP1,550,000$46.5M
6AMERIPRISE FINANCIAL INC1,424,674$42.7M
7DME Capital Management, LP482,746$14.5M
8SEGALL BRYANT & HAMILL, LLC426,412$12.8M
9Point72 Asset Management, L.P.332,125$10.0M
10RENAISSANCE TECHNOLOGIES LLC315,400$9.5M
11BlackRock, Inc.312,106$9.4M
12D. E. Shaw & Co., Inc.215,718$6.5M
13UBS Group AG175,289$5.3M
14DAFNA Capital Management LLC130,175$3.9M
15CITADEL ADVISORS LLC124,428$3.7M